Cargando…
The interplay of FLT3 and CXCR4 in acute myeloid leukemia: an ongoing debate
FLT3 mutations are very frequent in AML and utilization of FLT3 inhibitors as approved treatment options are very common. Despite the initial success of inhibitor treatment, the development of resistances against this treatment is a major challenge in AML therapy. One of the mechanisms causing resis...
Autores principales: | Klement, Laura, Drube, Julia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10577206/ https://www.ncbi.nlm.nih.gov/pubmed/37849810 http://dx.doi.org/10.3389/fonc.2023.1258679 |
Ejemplares similares
-
Developments and challenges of FLT3 inhibitors in acute myeloid leukemia
por: Ge, Shuai-Shuai, et al.
Publicado: (2022) -
CPX-351 in FLT3-mutated acute myeloid leukemia
por: Andrews, Claire, et al.
Publicado: (2023) -
FLT3 Mutations in Acute Myeloid Leukemia: Key Concepts and Emerging Controversies
por: Kennedy, Vanessa E., et al.
Publicado: (2020) -
Case Report: A Novel Activating FLT3 Mutation in Acute Myeloid Leukemia
por: Bruno, Samantha, et al.
Publicado: (2021) -
FLT3-TKD in the prognosis of patients with acute myeloid leukemia: A meta-analysis
por: Li, Shuping, et al.
Publicado: (2023)